In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and - resistant clinical isolates

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 11, 1997, Pages 2367-2373

  Chong, K T ^a   Pagano, P J ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; RITONAVIR; TIPRANAVIR; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MATHEMATICAL ANALYSIS; MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS ISOLATION;

EID: 0030671536     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.11.2367     Document Type: Article

References (42)

1. Belen'kii, M. S., and R. F. Schinazi. 1994. Multiple drug effect analysis with confidence interval. Antivir. Res. 25:1-11.
2. Bernard, H., O. Rutschmann, M. Fathi, V. Gabriel, A. Mendoula, I. von Overbeck, and A. Iten. 1996. Treatment of advanced HIV infection with ritonavir plus saquinavir, abstr. LB.B.6030, p. 28. In Abstracts of the XI International Conference on AIDS. International Conference on AIDS Society.
3. Bianchi, V., S. Borella, F. Calderazzo, P. Ferraro, L. Chieco-Bianchi, and P. Reichard. 1994. Inhibition of ribonucleotide reductase by 2′-substituted deoxycytidine analogs: possible application in AIDS treatment. Proc. Natl. Acad. Sci. USA 91:8403-8407.
4. Borin, M. Personal communication.
5. Boucher, C. 1996. Rational approaches to resistance: using saquinavir. AIDS 10(Suppl. 1):S15-S19.
6. Cameron, W., E. Sun, M. Markowitz, C. Farthing, D. McMahon, D. Poretz, C. Cohen, S. Follansbee, D. Ho, J. Mellors, A. Hsu, G. F. Grannenman, R. Maki, M. Salgo, J. Court, and J. Leonard. 1996. Combination use of ritonavir and saquinavir in HIV-infected patients: prehmmary safety and activity data, abstr. Th.B.934, p. 20. In Abstracts of the XI International Conference on AIDS. International Conference on AIDS Society.
7. Chong, K.-T., and P. J. Pagano. 1997. Inhibition of human immunodeficiency virus 1 infection in vitro by combination of delavirdine, zidovudine and didanosine. Antivir. Res. 34:51-63.
8. Chong, K.-T., P. J. Pagano, and R. R. Hinshaw. 1994. Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3′-azido-3′-deoxythymidine or 2′,3′-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro. Antimicrob. Agents Chemother. 38:288-293.
9. Chou, T.-C. 1991. The median-effect principle and the combination index to quantitation of synergism and antagonism, p. 61-102. In T.-C. Chou and D. C. Rideout (ed.), Synergism and antagonism in chemotherapy. Academic Press, Inc., New York, N.Y.
10. Chou, T.-C., and P. J. Talalay. 1984. Quantitative analysis of dose effect relationships: the combined effects of multiple drugs of enzyme inhibitors. Adv. Enzyme Regul. 22:27-55.
11. Coffin, J. M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. Science 267:483-489.
12. Collier, A. C., R. W. Coombs, D. A. Schoenfeld, R. L. Bassett, J. Timpone, A. Baurch, M. Jones, K. Facey, C. Whitacre, V. J. McAuliffe, H. M. Friedman, T. C. Merigan, R. C. Reichman, C. Hooper, and L. Corey. 1996. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N. Engl. J. Med. 334:1011-1017.
13. Collier, A. C., R. W. Coombs, D. A. Schoenfeld, R. Bassett, A. Baruch, and L. Corey. 1996. Combination therapy with zidovudine, didanosine and saquinavir. Antivir. Res. 29:99.
14. Condra, J. H., D. J. Holder, W. A. Schleif, O. M. Blahy, R. M. Danovich, L. J. Gabreylski, D. J. Graham, D. Laird, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, T. Yang, J. A. Chodakewitz, P. J. Deutsch, R. Y. Leavitt, F. E. Massari, J. W. Mellors, K. E. Squires, R. T. Steigbigel, H. Teppler, and E. A. Emini. 1996. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Virol. 70:8270-8276.
15. Condra, J. H., W. A. Schleif, O. M. Blahy, L. J. Gabryelski, D. J. Graham, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, D. Titus, T. Yang, H. Teppler, K. E. Squires, P. J. Deutsch, and E. E. Emini. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571.
16. Danner, S. A., A. Carr, J. M. Leonard, L. M. Lehman, F. Gudiol, J. Gonzales, A. Raventos, R. Rubio, E. Bouza, V. Pintado, A. Gil Aguado, J. Garcia de Lomas, R. Delgado, J. C. C. Borleffs, A. Hsu, J. Valdes, C. A. B. Boucher, and D. A. Cooper. 1995. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N. Engl. J. Med. 333: 1528-1533.
17. Deeks, S. G., M. Smith, M. Holodniy, and J. O. Kahn. 1997. HIV-1 protease inhibitors - a review for clinicians. JAMA 277:145-153.
18. Deminie, C. A., C. M. Bechtold, D. Stock, M. Alam, F. Djang, A. H. Balch, T.-C. Chou, M. Prichard, R. J. Colonno, and P. F. Lin. 1996. Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication. Antimicrob. Agents Chemother. 40:1346-1351.
19. Eron, J. J., Jr., V. A. Johnson, D. P. Merrill, T.-C. Chou, and M. S. Hirsch. 1992. Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2′,3′-dideoxycytidine in vitro. Antimicrob. Agents Chemother. 36:1559-1562.
20. Gao, W., D. G. Johns, and H. Mitsuya. 1994. Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2′,3′-dideoxynucleotides. Mol. Pharmacol. 46:767-772.
21. Gulick, R., J. Mellors, D. Havlir, J. Eron, C. Gonzelez, D. McMahon, D. Richman, F. Valentine, L. Jonas, A. Meibohm, R. Chiou, P. Deutsch, E. Emini, and J. Chodakewitz. 1996. Potent and sustained antiretroviral activity of indinavir in combination with zidovudine and lamivudine, abstr. LB7. In Abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections. Infectious Diseases Society of America for the Foundation of Retrovirology and Human Health, Alexandria, Va.
22. Ho, D. D., A. U. Neuman, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
23. Johnson, V. A., D. P. Merrill, J. A. Videler, T.-C. Chou, R. E. Byington, J. J. Eron, R. T. D'Aquila, and M. S. Hirsch. 1991. Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. J. Infect. Dis. 164:646-655.
24. Karlsson, A., P. Reichard, and F. Eckstein. 1989. Hydroxyurea increases the phosphorylation of 3′-fluorothymidine and 3′-azidothymidine in CEM cells. Eur. J. Biochem. 186:689-694.
25. Kempf, D. J., K. C. Marsh, J. F. Denissen, E. McDonald, S. Vasavanonda, and C. A. Flentge, et al. 1995. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. USA 92:2484-2488.
26. Kempf, D. J., K. C. Marsh, G. Kumar, A. D. Rodrigues, J. F. Denissen, E. McDonald, M. J. Kukulka, A. Hsu, G. R. Granneman, P. A. Baroldi, E. Sun, D. Pizzuti, J. J. Plattner, D. W. Norbeck, and J. M. Leonard. 1997. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother. 41:654-660.
27. Markowitz, M., M. Saag, W. G. Powderly, A. M. Hurley, A. Hsu, J. M. Valdez, D. Henry, F. Sattler, A. La Marca, J. M. Leonard, and D. D. Ho. 1995. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N. Engl. J. Med. 333:1534-1539.
28. Mathez, D., P. D. Truchis, I. Gorin, C. Katalama, G. Pialoux, A. G. Saimot, R. Tubiana, J. P. Chauvin, P. Bagnarelli, M. Clementi, and J. Leibowitch. 1996. Ritonavir, AZT, DDC, as a triple combination in AIDS patients, abstr. 285, p. 06. In Abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections. Infectious Diseases Society of America for the Foundation of Retrovirology and Human Health, Alexandria, Va.
29. Molla, A., M. Korneyeva, Q. Gao, S. Vasavanonda, P. J. Schipper, H.-M. Mo, M. Markowitz, T. Chernyavskiy, P. Niu, N. Lyons, A. Hsu, G. R. Granneman, D. D. Ho, C. A. B. Boucher, J. M. Leonard, D. W. Norbeck, and D. J. Kempf. 1996. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2:760-766.
30. Partaledis, J. A., K. Yamaguchi, M. Tisdale, E. E. Blair, C. Falcione, B. Maschera, R. E. Myers, S. Pazhanisamy, O. Futer, A. B. Cullinan, C. M. Stuver, R. A. Byrn, and D. J. Livingston. 1995. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J. Virol. 69:5228-5235.
31. Patick, A. K., H. Mo, M. Markowitz, K. Appelt, B. Wu, L. Musick, V. Kalish, S. Kaldor, S. Reich, and S. Webber. 1996. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob. Agents Chemother. 40:292-297.
32. Poppe, S. M., D. E. Slade, K.-T. Chong, R. R. Hinshaw, P. J. Pagano, M. Markowitz, D. D. Ho, H. Mo, R. R. Gorman III, T. J. Dueweke, S. Thaisrivongs, and W. G. Tarpley. 1997. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor Antimicrob. Agents Chemother. 41:1058-1063.
33. Prichard, M. N., L. E. Prichard, and C. Shipman, Jr. 1993. Strategic design and three-dimensional analysis of antiviral drug combinations. Antimicrob. Agents Chemother. 37:540-545.
34. Roberts, N. A. 1995. Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors. AIDS 9(Suppl. 2):S27-S32.
35. Schapiro, J. M., M. A. Winters, F. Stewart, B. Efron, J. Norris, M. J. Kozal, and T. C. Merigan. 1996. The effect of high-dose saquinavir on viral load and CD4(+) T-cell counts in HIV-infected patients. Ann. Intern. Med. 24:1039-1050.
36. Schinazi, R. F. 1991. Combined chemotherapeutic modalities for viral infections: rationale and clinical potential, p. 109-182. In T.-C. Chou and D. C. Rideout (ed.), Synergism and antagonism in chemotherapy. Academic Press, Inc., New York, N.Y.
37. Schinazi, R. F., B. A. Larder, and J. W. Mellors. 1996. Mutations in retroviral genes associated with drug resistance. Int. Antivir. News 4:95-107.
38. Schmit, J. C., L. Ruiz, B. Clotet, A. Raventos, J. Tor, J. Leonard, J. Desmyter, E. Declercq, and A. M. Vandamme. 1996. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 10:995-999.
39. St. Clair, M. H., J. Millard, J. Rooney, M. Tisdale, N. Parry, B. M. Sadler, M. R. Blum, and G. Painter. 1996. In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents. Antivir. Res. 29: 53-56.
40. Thaisrivongs, S., H. I. Skulnick, S. R. Turner, J. W. Strohbach, R. A. Tommasi, P. D. Johnson, P. A. Aristoff, T. M. Judge, R. B. Gammill, J. K. Morris, K. R. Romines, R. A. Chrusciel, R. R. Hinshaw, K.-T. Chong, W. G. Tarpley, S. M. Poppe, D. E. Slade, J. C. Lynn, M.-M. Horng, P. K. Tomich, E. P. Seest, L. A. Dolak, W. J. Howe, G. M. Howard, F. J. Schwende, L. N. Toth, G. E. Padbury, G. J. Wilson, L. Shiou, G. L. Zipp, K. F. Wilkinson, B. D. Rush, M. J. Ruwart, K. A. Koeplinger, Z. Zhao, S. Cole, R. M. Zaya, T. J. Kakuk, M. N. Janakiraman, and K. D. Watenpaugh. 1996. Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors. J. Med. Chem. 39:4349-4353.
41. Tisdale, M., R. E. Myers, B. Maschera, N. R. Parry, N. M. Oliver, and E. D. Blair. 1995. Cross-resistance analysis of HIV-1 variants individually selected for resistance to five different protease inhibitors. Antimicrob. Agents Chemother. 39:1704-1710.
42. Vella, S., C. Galluso, G. Giannini, M. F. Pirillo, I. Duncan, H. Jacobsen, M. Andreoni, L. Sarmati, and L. Ercoli. 1996. Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy - CD4+ lymphocyte plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity. Antivir. Res. 29:91-93.